<DOC>
	<DOCNO>NCT01896102</DOCNO>
	<brief_summary>This trial ass efficacy safety autologous CD34+ hematopoietic stem cell , transduce ex-vivo Lenti-D lentiviral vector , treatment cerebral adrenoleukodystrophy ( CALD ) . A subject 's blood stem cell collect modify use Lenti-D lentiviral vector encode human adrenoleukodystrophy protein . After modification Lenti-D lentiviral vector , cell transplant back subject follow myeloablative conditioning .</brief_summary>
	<brief_title>A Phase 2/3 Study Efficacy Safety Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector Treatment Cerebral Adrenoleukodystrophy ( CALD )</brief_title>
	<detailed_description />
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<criteria>1 . Informed consent obtain competent custodial parent guardian legal capacity execute local IRB/Independent Ethics Committee ( IEC ) approve consent ( informed assent seek capable subject , accordance directive IRB/IEC local requirement ) . 2 . Males age 17 year younger , time parental/guardian consent , appropriate , subject assent . 3 . Active cerebral ALD define : 1 . Elevated VLCFA value , 2 . Active CNS disease establish central radiographic review brain MRI demonstrating : i. Loes score 0.5 9 ( inclusive ) 34point scale , ii . Gadolinium enhancement MRI demyelinating lesion . 4 . Neurological Function Score ( NFS ) ≤ 1 . 1 . Receipt allogeneic transplant gene therapy . 2 . Availability willing 10/10 HLAmatched sibling donor ( exclude female heterozygote ) . 3 . Use statin , Lorenzo 's Oil , dietary regimen use low VLCFA level . Note : subject must discontinue use medication time consent . 4 . Receipt investigational study drug procedure within 3 month Screening might confound study outcome . Use investigational study drug prohibit throughout course study . 5 . Any condition make impossible perform MRI study ( include allergy anesthetic contrast agent ) . 6 . Hematological compromise evidence : Peripheral blood ANC count &lt; 1500 cells/mm3 , Platelet count &lt; 100,000 cells/mm3 , Hemoglobin &lt; 10 g/dL . Uncorrected bleed disorder . 7 . Hepatic compromise evidence : Aspartate transaminase ( AST ) value &gt; 2.5×ULN Alanine transaminase ( ALT ) value &gt; 2.5×ULN Total bilirubin value &gt; 3.0 mg/dL , except diagnosis Gilbert 's Syndrome subject otherwise stable 8 . Renal compromise evidence abnormal renal function ( actual calculate creatinine clearance &lt; 50 mL/min ) 9 . Cardiac compromise evidence leave ventricular ejection fraction &lt; 40 % 10 . Immediate family member know suspected familial cancer syndrome ( include limit hereditary breast ovarian cancer syndrome , hereditary nonpolyposis colorectal cancer syndrome , familial adenomatous polyposis ) . 11 . Clinically significant active bacterial , viral , fungal , parasitic , prionassociated infection 12 . Positive human immunodeficiency virus type 1 2 ( HIV1 , HIV2 ) ; hepatitis B ; hepatitis C ; human T lymphotrophic virus 1 ( HTLV1 ) . ( Note subject vaccinate hepatitis B [ hepatitis B surface antibodypositive ] negative marker prior hepatitis B infection [ eg , negative hepatitis B core antibody ( Ab ) ] eligible . Subjects past exposure HBV [ HBcAb positive and/or HBeAb positive ] also eligible study provide negative test HBV DNA . Also note subject positive antihepatitis C antibody eligible long negative hepatitis C viral load ) . 13 . Any clinically significant cardiovascular pulmonary disease , disease condition would contraindicate study procedure . 14 . Absence adequate contraception fertile subject . Male subject female partner require use two different effective method contraception Screening least 6 month drug product infusion .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adrenoleukodystrophy</keyword>
	<keyword>X-linked adrenoleukodystrophy</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Hematopoietic stem cell</keyword>
</DOC>